Ann: H1 2023 Preclinical and Clinical Programs Update, page-104

They (dexrazoxane is the only one) were approved when dose of anthracyclines used were much higher and it has a label indication only for women who have been exposed to more than 300mg/m2 of doxorubicin. Since almost no women these day are exposed to doses this high the data is now irrelevant.

Here is the FDA label indication:

ZINECARD® (dexrazoxane) for injection
Initial U.S. Approval: 1995
INDICATIONS AND USAGE

ZINECARD is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use ZINECARD with doxorubicin initiation.


https://en.wikipedia.org/wiki/Dexrazoxane